| Name | BioPharma Credit |
|---|---|
| Epic | BPCP |
| Isin | GB00BDGKMY29 |
| Industry |
| Latest share price | 70.70p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £0.00 | Debt ratio | n/a |
| Shares in issue | 0.00 | Debt-to-equity ratio | n/a |
| P/E ratio | 7.5 | Assets / equity ratio | n/a |
| Total dividends per share | 7.25¢ | Price to book value | n/a |
| Dividend yield | 7.3 | ROCE | |
| Dividend cover | 1.85 | EPS growth | |
| Earning per share | 12.93 | 52-week high / low | 65.20p / 74.60p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| Special | 2023-12-07 | 2024-01-05 | 2.00¢ |
| 3rd Interim | 2023-12-07 | 2024-01-05 | 1.75¢ |
| 2nd Interim | 2023-08-17 | 2023-09-15 | 1.75¢ |
| 1st Interim | 2023-04-27 | 2023-05-26 | 1.75¢ |
| Special | 2023-03-30 | 2023-04-28 | 1.58¢ |
| 4th Interim | 2023-03-30 | 2023-04-28 | 1.75¢ |
| Special | 2022-10-20 | 2022-11-18 | 4.50¢ |
| 3rd Interim | 2022-10-20 | 2022-11-18 | 1.75¢ |
| 2nd Interim | 2022-08-25 | 2022-09-23 | 1.75¢ |
| Company name | BioPharma Credit |
|---|---|
| Address | 51 New North Road, Exeter, United Kingdom, EX4 4EP |
| Telephone | +44 (0)1392 477500 |
| Website | http://www.bpcruk.com |
| Director | Position |
|---|---|
| Mr Harry Abraham Hyman | Chairman |
| Ms Sapna Shah | Non-Executive Director |
| Mr Duncan W A Budge | Senior Independent Director |
| Ms Stephanie Léouzon | Independent Non-Executive Director |
| Mr Colin Bond | Independent Non-Executive Director |
| Mr Rolf Soderstrom | Independent Non-Executive Director |
| Assets $ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Reporting date | 31/12/22 | 31/12/21 | 31/12/20 |
| Intangible asssets and goodwill | n/a | n/a | n/a |
| Investments and other non-current assets | |||
| Total non-current assets | |||
| Inventory / work in progress | |||
| Trade and other receivables | |||
| Cash and equivalents | 0.12 | 0.09 | 193.27 |
| Other current assets and asset held for resale | |||
| Total of all assets | 1.36 | 1.37 | 1388.31 |
| Liabilities $ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Short term liabilities | |||
| Long term liabilities | |||
| Other liabilites / pension etc | |||
| Total of all liabilities | 0.03 | 0.01 | 9.39 |
| Net assets $ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Net assets | 1.34 | 1.36 | 1378.92 |
| Equity $ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Share capital | |||
| Minority interests | n/a | n/a | n/a |
| Retained earnings | |||
| Share premium account | 0.61 | 0.61 | 607.12 |
| Total equity |
| Income $ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Turnover | 212.22 | 127.63 | 100.55 |
| Operating profit | 176.39 | 108.73 | 79.67 |
| Pre-tax profit | 176.39 | 108.73 | 79.67 |